Matthias Rau
Aachen, NW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Renal Denervation Improves Uremic Cardiomyopathy in Rats With Chronic Kidney Disease.
Journal: Journal of the American Heart Association
Published: July 21, 2025
Adjustment of the SMART risk score by bioactive adrenomedullin enables a more accurate prediction of mortality in patients with ASCVD.
Journal: Atherosclerosis
Published: December 04, 2024
Proenkephalin A 119-159 (penKid) and mortality in stable patients at high cardiovascular risk.
Journal: Clinical kidney journal
Published: April 09, 2024
Empagliflozin Improves Left Atrial Strain in Patients With Type 2 Diabetes: Data From a Randomized, Placebo-Controlled Study.
Journal: Circulation. Cardiovascular imaging
Published: April 18, 2023
Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure.
Journal: ESC heart failure
Published: February 01, 2022
The gut hormone glucose-dependent insulinotropic polypeptide is downregulated in response to myocardial injury.
Journal: Cardiovascular diabetology
Published: November 23, 2021
Effects of empagliflozin on markers of calcium and phosphate homeostasis in patients with type 2 diabetes - Data from a randomized, placebo-controlled study.
Journal: Bone reports
Published: October 28, 2021
Effects of empagliflozin on erythropoiesis in patients with type 2 diabetes: Data from a randomized, placebo-controlled study.
Journal: Diabetes, obesity & metabolism
Published: April 10, 2021
Human and mouse non-targeted metabolomics identify 1,5-anhydroglucitol as SGLT2-dependent glycemic marker.
Journal: Clinical and translational medicine
Published: March 22, 2021
Effects of empagliflozin on lipoprotein subfractions in patients with type 2 diabetes: data from a randomized, placebo-controlled study.
Journal: Atherosclerosis
Published: January 13, 2021
Peptide YY (PYY) Is Associated with Cardiovascular Risk in Patients with Acute Myocardial Infarction.
Journal: Journal of clinical medicine
Published: October 28, 2020
Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study.
Journal: Cardiovascular diabetology
Published: July 19, 2020
Last Updated: 09/26/2026